From the Guidelines
New York patients requiring stem cell transplants should be treated at specialized and experienced centers, such as Memorial Sloan Kettering Cancer Center, NewYork-Presbyterian Hospital, or Mount Sinai Hospital, which offer a multidisciplinary approach and the possibility of clinical trials. When selecting a center, it is crucial to consider factors like procedure volume, team experience, and outcomes data, as these can significantly impact morbidity, mortality, and quality of life 1.
Key Considerations for Stem Cell Transplant Centers
- High procedure volumes
- Experienced transplant teams
- Strong outcomes data
- Multidisciplinary care teams, including transplant physicians, nurses, pharmacists, and supportive care specialists
- Specific expertise in treating particular conditions, such as leukemia, lymphoma, or multiple myeloma
Treatment Approach
The treatment approach for stem cell transplants typically involves conditioning therapy, which may include chemotherapy agents like cyclophosphamide, busulfan, or melphalan, often at myeloablative or reduced-intensity doses depending on patient factors, followed by the stem cell infusion and a recovery period requiring close monitoring 1.
Importance of Specialized Centers
As emphasized in the guidelines for the diagnosis, treatment, and follow-up of acute myeloblastic leukemias in adult patients, AML should only be treated in specialized and experienced centers offering a multidisciplinary approach, and the possibility of clinical trials 1. This is crucial for ensuring the best possible outcomes for patients undergoing stem cell transplants.
From the Research
New York Centers for Stem Cell Transplants
- There are no specific studies provided that directly mention New York centers for stem cell transplants. However, the studies do discuss the effectiveness and safety of stem cell transplants in general.
- Autologous stem cell transplantation (ASCT) is a significant and innovative strategy for treating diseases such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, and AL amyloidosis 2.
- Allogeneic stem cell transplant (allo-SCT) is a potentially curative option for patients with acute myeloid leukemia (AML) and multiple myeloma, but it is limited by mortality 3, 4.
- Tandem autologous stem cell transplantation has been shown to improve outcomes in newly diagnosed multiple myeloma patients with extramedullary disease and high-risk cytogenetics 5.
- The choice between autologous and allogeneic hematopoietic stem cell transplantation as front-line treatment for adult secondary acute myeloid leukemia patients depends on various clinical factors, including cytogenetic/genetic risk 6.